Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab era.
carcinoma
hospitalization
intensity-modulated
lung neoplasms
lymphopenia
non-small cell lung
proton therapy
radiotherapy
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
31 Jan 2024
31 Jan 2024
Historique:
revised:
25
11
2023
received:
24
10
2023
accepted:
05
12
2023
medline:
31
1
2024
pubmed:
31
1
2024
entrez:
31
1
2024
Statut:
aheadofprint
Résumé
It was hypothesized that use of proton beam therapy (PBT) in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiation and consolidative immune checkpoint inhibition is associated with fewer unplanned hospitalizations compared with intensity-modulated radiotherapy (IMRT). Patients with locally advanced non-small cell lung cancer treated between October 2017 and December 2021 with concurrent chemoradiation with either IMRT or PBT ± consolidative immune checkpoint inhibition were retrospectively identified. Logistic regression was used to assess the association of radiation therapy technique with 90-day hospitalization and grade 3 (G3+) lymphopenia. Competing risk regression was used to compare G3+ pneumonitis, G3+ esophagitis, and G3+ cardiac events. Kaplan-Meier method was used for progression-free survival and overall survival. Inverse probability treatment weighting was applied to adjust for differences in PBT and IMRT groups. Of 316 patients, 117 (37%) received PBT and 199 (63%) received IMRT. The PBT group was older (p < .001) and had higher Charlson Comorbidity Index scores (p = .02). The PBT group received a lower mean heart dose (p < .0001), left anterior descending artery V15 Gy (p = .001), mean lung dose (p = .008), and effective dose to immune circulating cells (p < .001). On inverse probability treatment weighting analysis, PBT was associated with fewer unplanned hospitalizations (adjusted odds ratio, 0.55; 95% CI, 0.38-0.81; p = .002) and less G3+ lymphopenia (adjusted odds ratio, 0.55; 95% CI, 0.37-0.81; p = .003). There was no difference in other G3+ toxicities, progression-free survival, or overall survival. PBT is associated with fewer unplanned hospitalizations, lower effective dose to immune circulating cells and less G3+ lymphopenia compared with IMRT. Minimizing dose to lymphocytes may be warranted, but prospective data are needed.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 American Cancer Society.
Références
Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342-2350. doi:10.1056/NEJMoa1809697
Chun SG, Hu C, Choy H, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. J Clin Oncol. 2017;35(1):56-62. doi:10.1200/JCO.2016.69.1378
Liao Z, Lee JJ, Komaki R, et al. Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small-cell lung cancer. J Clin Oncol. 2018;36(18):1813-1822. doi:10.1200/JCO.2017.74.0720
Yu NY, DeWees TA, Voss MM, et al. Cardiopulmonary toxicity following intensity-modulated proton therapy (IMPT) versus intensity-modulated radiation therapy (IMRT) for stage III non-small cell lung cancer. Clin Lung Cancer. 2022;23(8):e526-e535. doi:10.1016/j.cllc.2022.07.017
Kim N, Myoung Noh J, Lee W, et al. Proton beam therapy reduces the risk of severe radiation-induced lymphopenia during chemoradiotherapy for locally advanced non-small cell lung cancer: a comparative analysis of proton versus photon therapy. Radiother Oncol. 2021;156:166-173. doi:10.1016/j.radonc.2020.12.019
Boyce-Fappiano D, Nguyen QN, Chapman BV, et al. Single institution experience of proton and photon-based postoperative radiation therapy for non-small-cell lung cancer. Clin Lung Cancer. 2021;22(5):e745-e755. doi:10.1016/j.cllc.2021.02.002
Baumann BC, Mitra N, Harton JG, et al. Comparative effectiveness of proton vs photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer. JAMA Oncol. 2020;6(2):237. doi:10.1001/jamaoncol.2019.4889
Jin JY, Hu C, Xiao Y, et al. Higher radiation dose to the immune cells correlates with worse tumor control and overall survival in patients with stage III NSCLC: a secondary analysis of RTOG0617. Cancers. 2021;13(24):6193. doi:10.3390/cancers13246193
Common Terminology Criteria for Adverse Events (CTCAE). Published online 2017.
Kurz CF. Augmented inverse probability weighting and the double robustness property. Med Decis Making. 2022;42(2):156-167. doi:10.1177/0272989X211027181
Friedes C, Iocolano M, Ho Lee S, et al. The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC. Radiother Oncol. Published online November. 2023;190:110030. doi:10.1016/j.radonc.2023.110030
Yegya-Raman N, Ho Lee S, Friedes C, et al. Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidation. Radiother Oncol. 2023;190:110005. doi:10.1016/j.radonc.2023.110005
Gjyshi O, Xu T, Elhammali A, et al. Toxicity and survival after intensity-modulated proton therapy versus passive scattering proton therapy for NSCLC. J Thorac Oncol. 2021;16(2):269-277. doi:10.1016/j.jtho.2020.10.013
Friedes C, Chakrabarti T, Olson S, et al. Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy. Lung Cancer. 2021;154:36-43. doi:10.1016/j.lungcan.2021.01.022
Ladbury CJ, Rusthoven CG, Camidge DR, Kavanagh BD, Nath SK. Impact of radiation dose to the host immune system on tumor control and survival for stage III non-small cell lung cancer treated with definitive radiation therapy. Int J Radiat Oncol. 2019;105(2):346-355. doi:10.1016/j.ijrobp.2019.05.064
Cho Y, Park S, Byun HK, et al. Impact of treatment-related lymphopenia on immunotherapy for advanced non-small cell lung cancer. Int J Radiat Oncol. 2019;105(5):1065-1073. doi:10.1016/j.ijrobp.2019.08.047
Damen PJJ, Kroese TE, Van Hillegersberg R, et al. The influence of severe radiation-induced lymphopenia on overall survival in solid tumors: a systematic review and meta-analysis. Int J Radiat Oncol. 2021;111(4):936-948. doi:10.1016/j.ijrobp.2021.07.1695
McCall NS, McGinnis HS, Janopaul-Naylor JR, et al. Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era. Radiother Oncol. 2022;174:133-140. doi:10.1016/j.radonc.2022.07.015
Jing W, Xu T, Wu L, et al. Severe radiation-induced lymphopenia attenuates the benefit of durvalumab after concurrent chemoradiotherapy for NSCLC. JTO Clin Res Rep. 2022;3(9):100391. doi:10.1016/j.jtocrr.2022.100391
Xu C, Jin JY, Zhang M, et al. The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy. Radiother Oncol. 2020;146:180-186. doi:10.1016/j.radonc.2020.02.015
Qiu J, Lin H, Ke D, et al. Higher radiation dose on immune cells is associated with radiation-induced lymphopenia and worse prognosis in patients with locally advanced esophageal squamous cell carcinoma. Front Immunol. 2023;14:1066255. doi:10.3389/fimmu.2023.1066255
Yu Y, Fu P, Jin JY, et al. Impact of effective dose to immune cells (EDIC) on lymphocyte nadir and survival in limited-stage SCLC. Radiother Oncol. 2021;162:26-33. doi:10.1016/j.radonc.2021.06.020
Jensen GL, Blanchard P, Gunn GB, et al. Prognostic impact of leukocyte counts before and during radiotherapy for oropharyngeal cancer. Clin Transl Radiat Oncol. 2017;7:28-35. doi:10.1016/j.ctro.2017.09.008
Mohan R, Liu AY, Brown PD, et al. Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons. Neuro Oncol. 2021;23(2):284-294. doi:10.1093/neuonc/noaa182
De B, Ng SP, Liu AY, et al. Radiation-associated lymphopenia and outcomes of patients with unresectable hepatocellular carcinoma treated with radiotherapy. J Hepatocell Carcinoma. 2021;8:57-69. doi:10.2147/JHC.S282062
Fang P, Shiraishi Y, Verma V, et al. Lymphocyte-sparing effect of proton therapy in patients with esophageal cancer treated with definitive chemoradiation. Int J Part Ther. 2017;4(3):23-32. doi:10.14338/IJPT-17-00033.1
Wang X, Van Rossum PSN, Chu Y, et al. Severe lymphopenia during chemoradiation therapy for esophageal cancer: comprehensive analysis of randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy. Int J Radiat Oncol. 2023:S0360301623078525. Published online. doi:10.1016/j.ijrobp.2023.08.058
Li Y, Fan X, Yu Q, et al. Proton and carbon ion radiation therapy decreased severe lymphopenia by reducing thoracic vertebra and aortic doses in non-small cell lung cancer versus intensity modulated radiation therapy. Int J Radiat Oncol. 2023;116(3):579-589. doi:10.1016/j.ijrobp.2022.12.030
Giaddui T, Chen W, Yu J, et al. Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC. Radiat Oncol. 2016;11(1):66. doi:10.1186/s13014-016-0640-8